Navigation Links
Pazopanib Shows Positive in Advanced Renal Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma

CHICAGO, GlaxoSmithKline today announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC), ovarian cancer and soft tissue sarcoma (STS). These trials were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The results observed in these trials with pazopanib support further investigations.

Pazopanib is an oral, investigational angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-kit, important proteins in the angiogenic process. Angiogenesis, which is the growth of new blood vessels in the body, plays a critical role in the growth and spread of tumors.

About Renal cell carcinoma study. This ongoing Phase II randomized discontinuation study is evaluating patients with advanced or metastatic RCC who have not received prior systemic therapy or have failed one prior therapy (cytokine or bevacizumab-containing regimen). All patients received 800 mg of pazopanib taken orally, once-daily during a 12 week lead-in period. Based on data available on 60 patients at the time of a planned interim analysis, the Independent Data Monitoring Committee (IDMC) recommended that randomization to placebo for patients with stable disease should be discontinued. The study continued as an open-label, single- arm study with all patients receiving pazopanib.

The preliminary week 12 response rate for all 225 patients was 27%. In addition, stable disease was achieved in 46% of patients for a total disease control rate of 73%. Responses have been observed beyond week 12, and the overall response rate will be reported at study completion. Response was determined according to RECIST (Response Evaluation Criteria In Solid Tumors) which is a set of published rules that defines when cancer patients improve (respond), stay the same (stable), or worsen (progress) during tr
'"/>




Page: 1 2 3 4

Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. New Prostate Cancer Vaccine Shows Promise
3. Ebola Treatment Shows Promise
4. New Drug Shows Significant Improvement In HIV-related Heart Condition
5. Greek Study Shows Living In The Hills May Be Healthier
6. Research Shows Carbon Monoxide Prevents Inflammations
7. Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly
8. Novartis MS Drug Shows Promising Results
9. MRI Shows Emotional Changes During Menstrual Cycle
10. Bronchiolo-alveolar Carcinoma Shows Sonographic Pattern Of Pneumonia
11. AIDS drug GS 9137 Shows Promise
Post Your Comments:
(Date:7/25/2008)... Authority offers patients consumers tips and enco...nt safety, HARRISBURG, Pa., July 25 /PRNewswire-U...ority today supports "National Patient Safety Day"...and their families to,participate fully in their h...ing they can about their surgery or illness., "We...
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begin...l/ -- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ...ced today that its subsidiary has commenced commer...psules USP product in the 40mg,strength from its D...on,with the launch, Watson has 180 days of marketi...
(Date:7/25/2008)...ck to benefit ALS Therapy Alliance to be presented...ight, WOONSOCKET, R.I., July 25 /PRNewswire/ -- C...raised a record-breaking $4.4 million in just 21 d...gn for ALS research. This is,the seventh year of t...aised more than $15 million for ALS research. This...
(Date:7/25/2008)... The Retina Group of New York wi...lated macular degeneration especially designed for...ale Public Library at 116 Merritts Road, Farmingda...15. Attendance is free and refreshments will be pr...516) 939-6100. , Hicksvil...
Breaking Medicine News(10 mins):Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3
...UKTI) is looking for collaboration and interaction...ion of Indian Industry, CII had meetings with UKTI...ations and Indian Health care providers. David Ha...ing Indian health care providers such as Apollo Ho...
...l recognized, however, it is frequently difficult ...cular dietary component and a specific health endp...for environmental pollutants, as most of them reac... a number of studies have determined the occurrenc...
...e Federale de Lausanne) and the CHUV (Lausanne Uni...in the hair follicle belong to the true multipoten... many cell types needed for hair growth and follic... documented its findings in an advance online publ...
...odegenerative disorder with no known cause or cure... that time, we have come a long way in understandi...rized by symptoms of memory loss, confusion, impai...sorientation and loss of language skills. Mild co...
Other Medicine News:Health News:Athletes Are More Prone To Environmental Pollutants Due To Choice Of Diet 2Health News:PET Scanning can help in early detection of Alzheimer’s diseas 2
(Date:7/23/2008)... Study results pending publication in July print e... available on Web, INDIANAPOLIS, July 23 /PRNewsw...evaluating the use of N-terminal pro-B-type natriu...alue of NT-proBNP for risk,stratification in predi...V-AE) in patients treated with non-steroidal anti-...
(Date:7/23/2008)... BOSTON, July 23 /- FluoroPharma Inc....ing agents for the Positron Emission Tomography,(P... BFPET, its novel,Fluorine-18 labeled tracer for m...,s second cardiovascular product to complete Phase...agent, designed to assess the blood flow in the,he...
(Date:7/23/2008)... SEATTLE, July 23 /- Dendre...at it expects the Independent Data,Monitoring Comm... analysis,of overall survival relating to the Comp...denoCarcinoma Treatment, also known as D9902B) cli...E is the Company,s investigational,active cellular...
(Date:7/22/2008)... - Strong efficacy results from a multi-center 293....com , Toronto Stock Exchange Symbol: CYT, MONTR...Technologies,Inc., the global leader in cryotherap...ounced that results previously presented from thre...product, Arctic Front(R),were published earlier t...
Breaking Medicine Technology:Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3New AARP Report Finds Mixed Results Among State Governments Efforts to Balance Long Term Care Services Under Medicaid 23826 1New AARP Report Finds Mixed Results Among State Governments Efforts to Balance Long Term Care Services Under Medicaid 23826 2New AARP Report Finds Mixed Results Among State Governments Efforts to Balance Long Term Care Services Under Medicaid 23826 3RAC Companies Respond to CMS Report on RAC Demonstration Program 23824 1RAC Companies Respond to CMS Report on RAC Demonstration Program 23824 2Using Mediasite for Lecture Capture Found to Enhance Student Performance at Penn State Milton S Hershey Medical Center 23823 1Using Mediasite for Lecture Capture Found to Enhance Student Performance at Penn State Milton S Hershey Medical Center 23823 2Using Mediasite for Lecture Capture Found to Enhance Student Performance at Penn State Milton S Hershey Medical Center 23823 3Using Mediasite for Lecture Capture Found to Enhance Student Performance at Penn State Milton S Hershey Medical Center 23823 4Using Mediasite for Lecture Capture Found to Enhance Student Performance at Penn State Milton S Hershey Medical Center 23823 5NuVal 28TM 29 Nutritional Scoring System Will Debut in Major U S Chains This September 23821 1NuVal 28TM 29 Nutritional Scoring System Will Debut in Major U S Chains This September 23821 2NuVal 28TM 29 Nutritional Scoring System Will Debut in Major U S Chains This September 23821 3
... CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2007 -...used biopharmaceutical,company, announced today th... granted Fast Track designation for its novel hist...otherapy of,previously treated peripheral T-cell l...ed that it has reached an agreement with the,FDA u...
... MADISON, N.J., May 9 /PRNewswire-FirstCall/ -- W...d and Drug Administration,s (FDA),San Juan Distric...FDA re-inspection of its Guayama, Puerto Rico manu...classification of the site.,The new classification...r been corrected by the Company or do not merit an...
Other Medicine Technology:Gloucester Pharmaceuticals Receives Fast Track Designation for,Romidepsin in Peripheral T-Cell Lymphoma 2Gloucester Pharmaceuticals Receives Fast Track Designation for,Romidepsin in Peripheral T-Cell Lymphoma 3FDA Re-Inspection Results in Positive Re-Classification of Guayama,Facility 2FDA Re-Inspection Results in Positive Re-Classification of Guayama,Facility 3
The GENIE is the proven electrophoretic transfer apparatus incorporating state-of-the-art plate electrodes for the ultimate in field uniformity. Its design allows for a very close positioning of the
The HEP-3, with a transfer area of 35cmW x 45cmL, is designed specifically for the transfer of nucleic acids from sequencing gels to nylon membranes.
The Trans-Blot SD semi-dry transfer cell allows fast, efficient and economical blotting. Using a platinum-coated titanium plate as the anode and a stainless steel plate as the cathode, the Trans-Blot
...A and RNA from agarose gels to hybridization membr...nd efficiency of transfer by allowing high pressur...em allowing electrophoresis, gel treatment, transf...rs required for conventional methods ,Positive pre...
Medicine Products: